The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy

Journal of Experimental & Clinical Cancer Research

Chiyuan Ma²  Zhenfeng Lu³  Wanchun Li³  Sheng Wang²  Yuebing Hu²  Mamatemin Tohti²  Junyang Li²  Youwei Wang¹ 

[1] Department of Neurosurgery, Yangzhou No.1 People’s Hospital, The Second Clinical School of Yangzhou University, 368 Hanjiang Road, Yangzhou 225012, China;Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Nanjing 210002, China;Department of Pathology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Nanjing 210002, China

关键词: Bevacizumab;    Temozolomide;    Dopamine agonists;    VEGF;    MGMT;    Dopamine D2 receptors;   

Others  :  1136186
DOI  :  10.1186/s13046-014-0056-y

 received in 2014-02-11, accepted in 2014-06-27,  发布年份 2014

【 摘 要 】

Background

To study the expression of D2R, MGMT and VEGF for clinical significance in pituitary adenomas, and to predict the potential curative medical therapy of dopamine agonists, temozolomide and bevacizumab on pituitary adenomas.

Methods

Immunohistochemistry and western blot were performed to detect the expression of expression of D2R, MGMT and VEGF in pituitary adenoma tissue samples. The ratio of high expression of D2R, MGMT or VEGF in different subtypes of PA was compared by the use of chi-squared tests. The relationships between D2R, MGMT and VEGF expression were assessed by the Spearman rank correlation test. The association between their expression and clinical parameters was analyzed using a chi-squared test, or Fisher's exact probability test when appropriate.

Results

The data showed that in 197 different histological subtypes of pituitary adenomas (PAs), 64.9% of them were D2R high expression, 86.3% were MGMT low expression and 58.9% were VEGF high expression. D2R high expression existed more frequently in PRL- and GH- secreting PAs. MGMT low expression existed in all PA subtypes. VEGF high expression existed more frequently in PRL, ACTH, FSH secreting and non-functioning PAs. The data of western blot also support the results. Spearman's rank correlation analysis showed that expression of MGMT was positively associated with D2R (r = 0.154, P = 0.031) and VEGF (r = 0.161, P = 0.024) in PAs, but no correlation was showed between D2R and VEGF expression (r = −0.025, P = 0.725 > 0.05). The association between their expression and clinical parameters was analyzed using a chi-squared test, or Fisher's exact probability test when appropriate, but the result showed no significant association.

Conclusions

PRL-and GH-secreting PAs exist high expression of D2R, responding to dopamine agonists; Most PAs exist low expression of MGMT and high expression of VEGF, TMZ or bevacizumab treatment could be applied under the premise of indications.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Bianchi A, Valentini F, Iuorio R, Poggi M, Baldelli R, Passeri M, Giampietro A, Tartaglione L, Chiloiro S, Appetecchia M, Gargiulo P, Fabbri A, Toscano V, Pontecorvi A, De Marinis L: Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 2013, 32:40. doi:10.1186/1756-9966-32-40 BioMed Central Full Text
• [2]Wan H, Chihiro O, Yuan S: MASEP gamma knife radiosurgery for secretory pituitary adenomas: experience in 347 consecutive cases. J Exp Clin Cancer Res 2009, 28:36. doi:10.1186/1756-9966-28-36 BioMed Central Full Text
• [3]Mantovani A, Macrì A: Endocrine effects in the hazard assessment of drugs used in animal production. J Exp Clin Cancer Res 2002, 21:445-456.
• [4]Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G: Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord 2009, 10:111-123.
• [5]Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S: High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Eur J Endocrinol 2009, 161:553-559.
• [6]Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K: Anti-VEGF therapy in pituitary carcinoma. Pituitary 2012, 15:445-449.
• [7]Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE: Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 2006, 105:621-626.
• [8]Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK, Renner U: Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J Endocrinol 2006, 191:249-261.
• [9]Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D: Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007, 25:1470-1475.
• [10]Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL: A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012, 77:567-571.
• [11]Niveiro M, Aranda FI, Peiro G, Alenda C, Pico A: Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol 2005, 36:1090-1095.
• [12]Knosp E, Steiner E, Kitz K, Matula C: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993, 33:610-618.
• [13]Guiramand J, Montmayeur JP, Ceraline J, Bhatia M, Borrelli E: Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins. J Biol Chem 1995, 270:7354-7358.
• [14]de Bruin C, Feelders RA, Waaijers AM, van Koetsveld PM, Sprij-Mooij DM, Lamberts SW, Hofland LJ: Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol 2009, 42:47-56.
• [15]Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G: Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002, 11:787-800.
• [16]Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A: Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999, 84:2518-2522.
• [17]Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM: Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab 2009, 94:1255-1263.
• [18]de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, van Aken MO, van der Lelij AJ, de Herder WW, Lamberts SW, Hofland LJ: Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009, 94:1118-1124.
• [19]Pivonello R, Ferone D, de Herder WW, Faggiano A, Bodei L, de Krijger RR, Lombardi G, Colao A, Lamberts SW, Hofland LJ: Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab 2007, 92:65-69.
• [20]Miller JW, Crapo L: The medical treatment of Cushing's syndrome. Endocr Rev 1993, 14:443-458.
• [21]Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S: Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 2008, 15:905-915.
• [22]Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E: Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011, 117:454-462.
• [23]McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ: Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 2009, 71:226-233.
• [24]Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr, Lopes MB: Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 2010, 95:E280-E290.
• [25]Salehi F, Scheithauer BW, Moyes VJ, Drake WM, Syro LV, Manoranjan B, Sharma S, Horvath E, Kovacs K: Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome. Endocr Pathol 2010, 21:227-229.
• [26]Salehi F, Scheithauer BW, Kovacs K, Horvath E, Syro LV, Sharma S, Manoranjan B, Cusimano M: O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas. Neurosurgery 2012, 70:491-496.
• [27]Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L: Vascular Endothelial Growth Factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 1999, 10:229-235.
• [28]Kurosaki M, Saegert W, Abe T, Ludecke DK: Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res 2008, 30:518-522.
• [29]Gagliano T, Filieri C, Minoia M, Buratto M, Tagliati F, Ambrosio MR, Lapparelli M, Zoli M, Frank G, degli Uberti E, Zatelli MC: Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Pituitary 2013, 16:91-100.
• [30]Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K: Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormones (Athens) 2011, 10:162-167.